<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="179412">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00759291</url>
  </required_header>
  <id_info>
    <org_study_id>2005P-001861</org_study_id>
    <nct_id>NCT00759291</nct_id>
  </id_info>
  <brief_title>The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome</brief_title>
  <official_title>The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that reducing the release of free fatty acids (FFA) from
      fat cells will restore insulin-mediated, endothelium-dependent vasodilation in people with
      the metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that acipimox, by decreasing plasma FFA concentrations, will augment
      endothelium-dependent vasodilation in conduit vessels and insulin-mediated vasodilation in
      forearm resistance arterioles in vivo, whole-body insulin sensitivity, and AKT (also known
      as Protein Kinase B) and endothelial nitric oxide synthase (eNOS) phosphorylation in skin
      biopsy specimens ex vivo, when compared with placebo.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute difference in flow-mediated, endothelium-dependent vasodilation of the brachial artery between the test agent and placebo</measure>
    <time_frame>following 1 week of drug/placebo</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acipimox</intervention_name>
    <description>250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Olbetam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with metabolic syndrome, defined as the presence of 3 of 5 components of the
             syndrome as defined by the National Cholesterol Education Program including:

               -  abdominal obesity

               -  elevated fasting blood sugar (110 mg/dL&lt; glucose &lt; 126 mg/dL)

               -  low HDL

               -  elevated fasting blood triglycerides (&gt; 150 mg/dL)

               -  hypertension (BP &gt; 140/90 mm HG)

          -  Normal cardiovascular examination

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Untreated hypercholesterolemia (LDL &gt; 75th percentile for age)

          -  Cigarette smoking within 1 year

          -  Renal insufficiency (creatinine &gt; 1.4 mg/dl)

          -  Blood dyscrasia

          -  Hepatic dysfunction (ALT &gt; 2x normal)

          -  Evident coronary/peripheral atherosclerosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua A. Beckman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 14, 2016</lastchanged_date>
  <firstreceived_date>September 24, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Joshua A. Beckman, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>free fatty acids</keyword>
  <keyword>insulin-mediated</keyword>
  <keyword>endothelium-dependent vasodilation</keyword>
  <keyword>metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acipimox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
